Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis
<h3>Aims</h3><p dir="ltr">This systematic review and meta-analysis aims to evaluate the safety and efficacy of the newer glucose lowering treatments on glycemic control, weight, blood pressure and hypoglycemia in patients with T2DM during Ramadan.</p><h3>Metho...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , |
| Published: |
2020
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513559477616640 |
|---|---|
| author | Hoda Gad (6470522) |
| author2 | Tabraiz Hayat (17052420) Hamad Al-Muhannadi (17052423) Balal Rasheed Malik (17052426) Paul Mussleman (12160883) Rayaz A. Malik (7372649) |
| author2_role | author author author author author |
| author_facet | Hoda Gad (6470522) Tabraiz Hayat (17052420) Hamad Al-Muhannadi (17052423) Balal Rasheed Malik (17052426) Paul Mussleman (12160883) Rayaz A. Malik (7372649) |
| author_role | author |
| dc.creator.none.fl_str_mv | Hoda Gad (6470522) Tabraiz Hayat (17052420) Hamad Al-Muhannadi (17052423) Balal Rasheed Malik (17052426) Paul Mussleman (12160883) Rayaz A. Malik (7372649) |
| dc.date.none.fl_str_mv | 2020-11-30T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.diabres.2020.108562 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Efficacy_and_safety_of_the_newer_oral_hypoglycemic_agents_in_patients_with_T2DM_during_Ramadan_A_systematic_review_and_meta-analysis/24204192 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Clinical sciences Medical biochemistry and metabolomics Pharmacology and pharmaceutical sciences Mathematical sciences Statistics Ramadan fasting Diabetes DPP-4i GLP-1 agonist SGLT-2i |
| dc.title.none.fl_str_mv | Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h3>Aims</h3><p dir="ltr">This systematic review and meta-analysis aims to evaluate the safety and efficacy of the newer glucose lowering treatments on glycemic control, weight, blood pressure and hypoglycemia in patients with T2DM during Ramadan.</p><h3>Methods</h3><p dir="ltr">A literature search was done in PubMed, Embase, and the Cochrane Library. Quality assessment was done using the ROBINS-I and Cochrane tools for risk of bias and analyses were performed using RevMan version 5.3.</p><h3>Results</h3><p dir="ltr">A total of 20 studies were included in the meta-analysis. Dipeptidyl peptidase-4 inhibitors (DPP-4i) led to a significant reduction in Hb<sub>A1c</sub> (%) (SMD -0.25) and a non-significant decrease in weight (kg) (SMD -1.06) during Ramadan. Glucagon-like peptide (GLP-1) agonist therapy was associated with a significant decrease in Hb<sub>A1c</sub> (%) (SMD -0.68) and a non-significant decrease in weight (kg) (SMD -2.57) and systolic blood pressure (SBP) (mmHg) (SMD -3.50) after Ramadan. Sodium-glucose co-transporter 2 inhibitor (SGLT-2i) therapy was associated with a significant decrease in Hb<sub>A1c</sub> (%) (SMD -0.51) and a non-significant decrease in weight (kg) (SMD -1.41), SBP (SMD -1.10) and diastolic blood pressure (DBP) (mmHg) (SMD -2.08) after Ramadan.</p><h3>Conclusions</h3><p dir="ltr">This systematic review and meta-analysis shows clinical benefits with the newer glucose lowering medications in patients with T2DM who fast during Ramadan.</p><h2>Other Information</h2><p dir="ltr">Published in: Diabetes Research and Clinical Practice<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.diabres.2020.108562" target="_blank">https://dx.doi.org/10.1016/j.diabres.2020.108562</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_a7e9b891680de51999d5407c4f2a8795 |
| identifier_str_mv | 10.1016/j.diabres.2020.108562 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/24204192 |
| publishDate | 2020 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysisHoda Gad (6470522)Tabraiz Hayat (17052420)Hamad Al-Muhannadi (17052423)Balal Rasheed Malik (17052426)Paul Mussleman (12160883)Rayaz A. Malik (7372649)Biomedical and clinical sciencesClinical sciencesMedical biochemistry and metabolomicsPharmacology and pharmaceutical sciencesMathematical sciencesStatisticsRamadan fastingDiabetesDPP-4iGLP-1 agonistSGLT-2i<h3>Aims</h3><p dir="ltr">This systematic review and meta-analysis aims to evaluate the safety and efficacy of the newer glucose lowering treatments on glycemic control, weight, blood pressure and hypoglycemia in patients with T2DM during Ramadan.</p><h3>Methods</h3><p dir="ltr">A literature search was done in PubMed, Embase, and the Cochrane Library. Quality assessment was done using the ROBINS-I and Cochrane tools for risk of bias and analyses were performed using RevMan version 5.3.</p><h3>Results</h3><p dir="ltr">A total of 20 studies were included in the meta-analysis. Dipeptidyl peptidase-4 inhibitors (DPP-4i) led to a significant reduction in Hb<sub>A1c</sub> (%) (SMD -0.25) and a non-significant decrease in weight (kg) (SMD -1.06) during Ramadan. Glucagon-like peptide (GLP-1) agonist therapy was associated with a significant decrease in Hb<sub>A1c</sub> (%) (SMD -0.68) and a non-significant decrease in weight (kg) (SMD -2.57) and systolic blood pressure (SBP) (mmHg) (SMD -3.50) after Ramadan. Sodium-glucose co-transporter 2 inhibitor (SGLT-2i) therapy was associated with a significant decrease in Hb<sub>A1c</sub> (%) (SMD -0.51) and a non-significant decrease in weight (kg) (SMD -1.41), SBP (SMD -1.10) and diastolic blood pressure (DBP) (mmHg) (SMD -2.08) after Ramadan.</p><h3>Conclusions</h3><p dir="ltr">This systematic review and meta-analysis shows clinical benefits with the newer glucose lowering medications in patients with T2DM who fast during Ramadan.</p><h2>Other Information</h2><p dir="ltr">Published in: Diabetes Research and Clinical Practice<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.diabres.2020.108562" target="_blank">https://dx.doi.org/10.1016/j.diabres.2020.108562</a></p>2020-11-30T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.diabres.2020.108562https://figshare.com/articles/journal_contribution/Efficacy_and_safety_of_the_newer_oral_hypoglycemic_agents_in_patients_with_T2DM_during_Ramadan_A_systematic_review_and_meta-analysis/24204192CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/242041922020-11-30T00:00:00Z |
| spellingShingle | Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis Hoda Gad (6470522) Biomedical and clinical sciences Clinical sciences Medical biochemistry and metabolomics Pharmacology and pharmaceutical sciences Mathematical sciences Statistics Ramadan fasting Diabetes DPP-4i GLP-1 agonist SGLT-2i |
| status_str | publishedVersion |
| title | Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis |
| title_full | Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis |
| title_fullStr | Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis |
| title_full_unstemmed | Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis |
| title_short | Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis |
| title_sort | Efficacy and safety of the newer oral hypoglycemic agents in patients with T2DM during Ramadan: A systematic review and meta-analysis |
| topic | Biomedical and clinical sciences Clinical sciences Medical biochemistry and metabolomics Pharmacology and pharmaceutical sciences Mathematical sciences Statistics Ramadan fasting Diabetes DPP-4i GLP-1 agonist SGLT-2i |